Immune precision

Rheos plans to bring precision medicine to immune diseases with $60M series A

Third Rock Ventures is taking a page from cancer and Orphan diseases by launching Rheos Medicines Inc. to identify novel biomarkers and targets that will enable patient stratification and the development of precision medicines for autoimmune and inflammatory diseases. The

Read the full 401 word article

User Sign In